The ABL Advisor Deal Tables
SELECTED TRANSACTION DETAILS
JPMorgan Chase Agents $1.3B in Financing for Catalent Pharma Solutions
|
Lenders/Participants
|
JPMorgan Chase Bank [Administrative Agent, Collateral Agent]
|
|
Structure
|
Term Loan, Revolver Increase
|
|
Amount
|
$1.300
Billion
|
|
Borrower(s)
|
Catalent Pharma Solutions, Inc.
|
|
Description
|
Catalent, Inc. completed the acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. In connection with the acquisition of Paragon, Catalent Pharma Solutions, Inc., as borrower, and certain other wholly owned subsidiaries of Catalent entered into an amendment, dated as of May 17, 2019, to its existing credit agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, to provide for, among other things, $950 million of incremental term loans and a $350 million increase to its revolving credit facility. The proceeds of the incremental term loans were used to fund a portion of the acquisition consideration and for general working capital purposes, to pay fees, costs and expenses incurred in connection with the transactions contemplated hereby, for capital expenditures of Paragon and to prepay a portion of the existing term loans.
|
|
Industry
|
Biologics
|
|
Location
|
NJ
|
| Related Tags |
JPMorgan Chase Bank
|
ABL Advisor
Deal Tables
2024
|
|
|
|